Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT5QYJ)

Drug Name

ATI-2173 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis B	1E51	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hepatitis B virus Polymerase (HBV P)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Telbivudine	DMSWUGE	Hepatitis B virus infection	1E51.0	Approved	[3]
NCO-48	DMUSPW5	Hepatitis B virus infection	1E51.0	Phase 1	[4]
Valtorcitabine	DMXQCBU	Hepatitis virus infection	1E50-1E51	Discontinued in Phase 2	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis B virus Polymerase (HBV P)	TTT4SY6	Q67889_HBV	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04847440) A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection. U.S. National Institutes of Health.
2	ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00836-20.
3	Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92.
4	Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects
5	Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci. 2008 Mar;97(3):1109-34.